SMC Ltd announced the acquisition of an end-to-end fill/finish facility in Charlotte, North Carolina. The facility enables SMC to offer a wider portfolio of services to its pharma clients including lab to market development, analytical services, device manufacture, fill/finish, final assembly, and secondary packaging.
The state-of-the-art facility compliments SMC’s footprints of global manufacturing capabilities and illustrates SMC’s commitment to the pharma services industry by offering high-speed, sterile fill finish lines with onsite formulation, compounding, and packaging capabilities.
VP and General Manager, Uri Baruch commented, “There are notable developments in the injectables market – the growth of more complex biologics and the increased interest in delivering large volumes of API. We believe our ability to deliver, at speed, fill volumes from 1ml to 50ml is an unmet need and is already attracting significant attention from our clients and partners.”
“SMC is recognized globally for its ability to deliver complex, complete drug delivery systems with unrivalled speed and agility. This acquisition not only adds to this capability, it reaffirms our commitment to the pharma market and completes another phase of our growth agenda.”
At SMC, we have a proud 36-year history of innovating for contract manufacturing and pharma services customers,” said Chetan Patel, SMC Ltd.’s CEO. “This new North Carolina facility is another example of SMC adding the expertise, capabilities and capacity our customers need in to be successful. We know North Carolina’s fill finish capabilities will allow SMC and our pharmaceutical customers to form deeper partnerships well into the future.”